U.S. markets open in 5 hours 58 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0900-0.7700 (-41.40%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.8600
Open1.4500
Bid0.0000 x 1200
Ask0.0000 x 1400
Day's Range1.0700 - 1.4600
52 Week Range1.0700 - 5.1900
Volume13,854,882
Avg. Volume1,065,170
Market Cap92.408M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.3090
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Abeona Therapeutics Announces Leadership and Board Transitions

    NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors. João Siffert, M.D. resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. On September 27, 2020, Brian Pereira, M.D., Stefano Buono, Stephen B. Howell, M.D., George Migausky and Shawn Tomasello each announced that they had stepped down from the Board, effective immediately. No director gave any reason for their resignation and no director indicated any disagreements with the Company. The Company is reviewing and exploring all strategic options and alternatives focused on advancing the Company’s mission and maximizing stakeholder value, including the sale of some or all of its assets or sale of the Company. There can be no assurance this strategic review will result in the completion of any particular course of action. There is no defined timeline for completion of the review process.About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-201 for CLN3 disease. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements about the Company exploring all strategic options, including the sale of some or all of its assets or sale of the Company. We have attempted to identify forward looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws. CONTACT: Investor Contact: Greg Gin VP, Investor Relations Abeona Therapeutics +1 (646) 813-4709 ggin@abeonatherapeutics.com Media Contact: Scott Santiamo Director, Corporate Communications Abeona Therapeutics +1 (718) 344-5843 ssantiamo@abeonatherapeutics.com

  • Why Abeona Therapeutics Is Trading Higher Today
    Benzinga

    Why Abeona Therapeutics Is Trading Higher Today

    Abeona Therapeutics (NASDAQ: ABEO) shares are trading higher on Friday after B. Riley FBR initiated coverage on the stock with a Buy rating and announced a price target of $5 per share.Abeona Therapeutics is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease.The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-50X for the treatment of retinal diseases.Abeona Therapeutics shares were up 14.80% at $2.25 at the time of publication on Friday. The stock has a 52-week high of $5.19 and a 52-week low of $1.35.Latest Ratings for ABEO DateFirmActionFromTo Sep 2020B. Riley FBRInitiates Coverage OnBuy May 2020RBC CapitalMaintainsOutperform Mar 2020RBC CapitalMaintainsOutperform View More Analyst Ratings for ABEO View the Latest Analyst RatingsSee more from Benzinga * Why Bloom Energy's Stock Is Trading Higher Today * Why Westport Fuel Systems Stock Is Trading Higher Today * Why Veritone's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For September 18, 2020

    Upgrades * For Fox Factory Holding Corp (NASDAQ: FOXF), Stifel upgraded the previous rating of Hold to the current rating Buy. Fox Factory Hldg earned $0.50 in the second quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Fox Factory Hldg shows a 52-week-high of $113.41 and a 52-week-low of $34.58. Moreover, at the end of the last trading period, the closing price was at $75.59. * Morgan Stanley upgraded the previous rating for II-VI Inc (NASDAQ: IIVI) from Equal-Weight to Overweight. For the fourth quarter, II-VI had an EPS of $1.18, compared to year-ago quarter EPS of $0.67. The stock has a 52-week-high of $52.97 and a 52-week-low of $19.00. At the end of the last trading period, II-VI closed at $37.89. * For Kinross Gold Corp (NYSE: KGC), BMO Capital upgraded the previous rating of Market Perform to the current rating Outperform. In the second quarter, Kinross Gold showed an EPS of $0.15, compared to $0.06 from the year-ago quarter. The current stock performance of Kinross Gold shows a 52-week-high of $10.21 and a 52-week-low of $2.72. Moreover, at the end of the last trading period, the closing price was at $9.37. * Stifel upgraded the previous rating for Dave & Buster's Entertainment Inc (NASDAQ: PLAY) from Hold to Buy. For the second quarter, Dave & Buster's Enter had an EPS of $1.24, compared to year-ago quarter EPS of $0.90. At the moment, the stock has a 52-week-high of $48.80 and a 52-week-low of $4.61. Dave & Buster's Enter closed at $14.12 at the end of the last trading period. * Morgan Stanley upgraded the previous rating for SunPower Corp (NASDAQ: SPWR) from Underweight to Equal-Weight. In the second quarter, SunPower showed an EPS of $0.22, compared to $0.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.57 and a 52-week-low of $4.03. SunPower closed at $9.89 at the end of the last trading period. Downgrades * For Apartment Investment & Management Co (NYSE: AIV), Citigroup downgraded the previous rating of Neutral to the current rating Sell. For the second quarter, Apartment Inv & Mgmt had an EPS of $0.63, compared to year-ago quarter EPS of $0.60. The current stock performance of Apartment Inv & Mgmt shows a 52-week-high of $55.68 and a 52-week-low of $24.53. Moreover, at the end of the last trading period, the closing price was at $36.38. * According to Citigroup, the prior rating for Mirati Therapeutics Inc (NASDAQ: MRTX) was changed from Buy to Neutral. Mirati Therapeutics earned $1.89 in the second quarter, compared to $1.26 in the year-ago quarter. The current stock performance of Mirati Therapeutics shows a 52-week-high of $171.48 and a 52-week-low of $66.01. Moreover, at the end of the last trading period, the closing price was at $161.97. * Wells Fargo downgraded the previous rating for NovoCure Ltd (NASDAQ: NVCR) from Overweight to Equal-Weight. NovoCure earned $0.02 in the second quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $110.87 and a 52-week-low of $53.40. NovoCure closed at $108.98 at the end of the last trading period. * According to Chardan Capital, the prior rating for Seres Therapeutics Inc (NASDAQ: MCRB) was changed from Buy to Neutral. Seres Therapeutics earned $0.28 in the second quarter, compared to $0.24 in the year-ago quarter. At the moment, the stock has a 52-week-high of $33.00 and a 52-week-low of $2.52. Seres Therapeutics closed at $26.86 at the end of the last trading period. * According to JP Morgan, the prior rating for Beyond Meat Inc (NASDAQ: BYND) was changed from Neutral to Underweight. Beyond Meat earned $0.02 in the second quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Beyond Meat shows a 52-week-high of $167.16 and a 52-week-low of $48.18. Moreover, at the end of the last trading period, the closing price was at $157.22. * Initiations * B. Riley FBR initiated coverage on Abeona Therapeutics Inc (NASDAQ: ABEO) with a Buy rating. The price target for Abeona Therapeutics is set to $5.00. Abeona Therapeutics earned $0.14 in the second quarter, compared to $0.49 in the year-ago quarter. The current stock performance of Abeona Therapeutics shows a 52-week-high of $5.19 and a 52-week-low of $1.35. Moreover, at the end of the last trading period, the closing price was at $1.96. * With a current rating of Buy, Berenberg initiated coverage on Ambarella Inc (NASDAQ: AMBA). The price target seems to have been set at $67.00 for Ambarella. In the second quarter, Ambarella showed an EPS of $0.06, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $73.59 and a 52-week-low of $36.02. At the end of the last trading period, Ambarella closed at $52.19. * Compass Point initiated coverage on Argo Group International Holdings Ltd (NYSE: ARGO) with a Buy rating. The price target for Argo Gr Intl Hldgs is set to $41.00. For the second quarter, Argo Gr Intl Hldgs had an EPS of $0.14, compared to year-ago quarter EPS of $0.48. The stock has a 52-week-high of $70.89 and a 52-week-low of $25.00. At the end of the last trading period, Argo Gr Intl Hldgs closed at $35.59. * With a current rating of Outperform, Cowen & Co. initiated coverage on BioLife Solutions Inc (NASDAQ: BLFS). The price target seems to have been set at $33.00 for BioLife Solutions. In the second quarter, BioLife Solutions showed an EPS of $0.01, compared to $0.04 from the year-ago quarter. The stock has a 52-week-high of $28.28 and a 52-week-low of $7.37. At the end of the last trading period, BioLife Solutions closed at $25.43. * Goldman Sachs initiated coverage on Intellia Therapeutics Inc (NASDAQ: NTLA) with a Buy rating. The price target for Intellia Therapeutics is set to $33.00. For the second quarter, Intellia Therapeutics had an EPS of $0.61, compared to year-ago quarter EPS of $0.56. The stock has a 52-week-high of $25.56 and a 52-week-low of $9.18. At the end of the last trading period, Intellia Therapeutics closed at $22.45. * With a current rating of Buy, Benchmark initiated coverage on MACOM Technology Solutions Holdings Inc (NASDAQ: MTSI). The price target seems to have been set at $47.00 for MACOM Technology. For the third quarter, MACOM Technology had an EPS of $0.33, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $44.69 and a 52-week-low of $15.03. At the end of the last trading period, MACOM Technology closed at $32.79. * With a current rating of Hold, Truist Securities initiated coverage on Strategic Education Inc (NASDAQ: STRA). The price target seems to have been set at $105.00 for Strategic Education. In the second quarter, Strategic Education showed an EPS of $2.06, compared to $1.59 from the year-ago quarter. The current stock performance of Strategic Education shows a 52-week-high of $187.97 and a 52-week-low of $87.80. Moreover, at the end of the last trading period, the closing price was at $93.80. * With a current rating of Buy, Citigroup initiated coverage on Utz Brands Inc (NYSE: UTZ). The price target seems to have been set at $21.00 for Utz Brands. At the moment, the stock has a 52-week-high of $19.16 and a 52-week-low of $15.98. Utz Brands closed at $17.91 at the end of the last trading period. * With a current rating of Buy, Stifel initiated coverage on Construction Partners Inc (NASDAQ: ROAD). The price target seems to have been set at $21.00 for Construction Partners. For the third quarter, Construction Partners had an EPS of $0.30, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $22.15 and a 52-week-low of $11.96. Construction Partners closed at $17.89 at the end of the last trading period. * With a current rating of Outperform, Wedbush initiated coverage on Retrophin Inc (NASDAQ: RTRX). The price target seems to have been set at $33.00 for Retrophin. For the second quarter, Retrophin had an EPS of $0.22, compared to year-ago quarter EPS of $0.58. The current stock performance of Retrophin shows a 52-week-high of $21.92 and a 52-week-low of $8.98. Moreover, at the end of the last trading period, the closing price was at $19.67. * Piper Sandler initiated coverage on Intuit Inc (NASDAQ: INTU) with an Overweight rating. The price target for Intuit is set to $351.00. Intuit earned $1.81 in the fourth quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $360.00 and a 52-week-low of $187.68. At the end of the last trading period, Intuit closed at $307.23.See more from Benzinga * A Look Into Blackstone Group's Debt * A Look Into Eli Lilly's Debt * Sanofi: Debt Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.